Benitec Biopharma (BLT) Short Interest
Benitec Biopharma (ASX:BLT) had 0.01% of shares reported as short positions as of 6 Jan 2020, representing 45,569 shares. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Benitec Biopharma
Benitec Biopharma Inc. is a clinical-stage biotechnology company headquartered in Hayward, California, focused on developing novel genetic medicines. Its proprietary DNA-directed RNA interference (ddRNAi) platform combines RNA interference with gene therapy to achieve sustained silencing of disease-causing genes with a single administration. The company is advancing ddRNAi-based therapeutics for chronic and life-threatening conditions, including Oculopharyngeal Muscular Dystrophy (OPMD).
Short position
Benitec Biopharma (ASX:BLT) has 0.01% of its shares on issue reported as short positions as of 6 Jan 2020, or about 45,569 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.40% in May 2017. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 37, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4BLT intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Benitec Biopharma
About
website
Be the first to discuss BLT
Start a research thread or post the first pulse update